Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?
- 1 June 2007
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (6) , 709-711
- https://doi.org/10.1136/ard.2007.071159
Abstract
A delineation of the differences in pathology between AS and RAKeywords
This publication has 23 references indexed in Scilit:
- Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitisArthritis & Rheumatism, 2007
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 2004
- Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during experimental osteoarthritisArthritis & Rheumatism, 2003
- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trialArthritis & Rheumatism, 2003
- Tumor necrosis factor α‐mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerinArthritis & Rheumatism, 2002
- Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritisArthritis & Rheumatism, 2001
- Wnt-14 Plays a Pivotal Role in Inducing Synovial Joint Formation in the Developing Appendicular SkeletonCell, 2001
- TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligandJournal of Clinical Investigation, 2000
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Expression of osteoclast differentiation factor in rheumatoid arthritisArthritis & Rheumatism, 2000